HAMLET is the first member of a new family of tumoricidal protein-lipid complexes that kill cancer cells broadly, while sparing healthy, differentiated cells. Many and diverse tumor cell types are sensitive to the lethal effect, suggesting that HAMLET identifies and activates conserved death pathways in cancer cells. Here, we investigated the molecular basis for the difference in sensitivity between cancer cells and healthy cells. Using a combination of small-hairpin RNA (shRNA) inhibition, proteomic and metabolomic technology, we identified the cMyc oncogene as one essential determinant of HAMLET sensitivity. Increased c-Myc expression levels promoted sensitivity to HAMLET and shRNA knockdown of c-Myc suppressed the lethal response, suggesting that oncogenic transformation with c-Myc creates a HAMLET-sensitive phenotype. Furthermore, HAMLET sensitivity was modified by the glycolytic state of tumor cells. Glucose deprivation sensitized tumor cells to HAMLET-induced cell death and in the shRNA screen, hexokinase 1 (HK1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 and hypoxia-inducible factor 1a modified HAMLET sensitivity. HK1 was shown to bind HAMLET in a protein array containing B8000 targets, and HK activity decreased within 15 min of HAMLET treatment, before morphological signs of tumor cell death. In parallel, HAMLET triggered rapid metabolic paralysis in carcinoma cells. Tumor cells were also shown to contain large amounts of oleic acid and its derivatives already after 15 min. The results identify HAMLET as a novel anti-cancer agent that kills tumor cells by exploiting unifying features of cancer cells such as oncogene addiction or the Warburg effect.
Introduction
Despite the molecular complexity of oncogenic transformation, cancer cells frequently suffer from 'oncogene addiction', and the disruption of a single oncogene can either reverse oncogenesis or be lethal (Weinstein and Joe, 2008) . The c-Myc oncogene is a classic example (Felsher and Bishop, 1999) and is deregulated in at least 40% of all human cancers (Dang et al., 2009) . The broad transforming effect of c-Myc has been explained by its ability to bind to promoters of at least 30% of all known genes (Dang et al., 2009) , and in transgenic mice, c-Myc overexpression combined with inhibition of apoptosis is sufficient to drive pancreatic cancer formation (Pelengaris et al., 2002) . More recently, inhibition of c-Myc was proposed to stop cancer growth and even allow tissue repair and reversion to a functional phenotype (Soucek et al., 2008) . Healthy cells, in contrast, retain a limited replicative potential, due to their susceptibility to programmed cell death, antigrowth signals and other molecular interactions that limit longevity and maintain normal tissue homeostasis Weinberg, 2000, 2011) .
Oncogene activity may also cause a shift in the glycolytic machinery (Hsu and Sabatini, 2008) , and cancer cells are highly dependent on glycolysis (Mathupala et al., 1997) . Glucose is first trapped inside cells by hexokinases 1 and 2 (HK1 and HK2) (Wilson, 2003) and then further converted to pyruvate. In contrast to healthy cells, cancer cells drive pyruvate to lactate conversion even in the presence of oxygen, a process known as the Warburg effect (Warburg, 1956) . Recent studies have shown that oxidative phosphorylation is functional in most cancer cells (Vander Heiden et al., 2009) and have proposed that the Warburg effect may reflect the expression of the pyruvate kinase isoform M2 (PKM2) (Christofk et al., 2008) , which catalyzes the dephosphorylation of phosphoenolpyruvate to pyruvate and is responsible for net ATP production within the glycolytic sequence. In contrast to healthy differentiated cells, embryonic cells and most cancer cells mainly express the M2 isoform (Mazurek et al., 2005) , and in some tumors, replacement of M2 by M1 reverses the Warburg effect and reduces tumorigenicity (Christofk et al., 2008) . In addition to PKM2, c-Myc has a fundamental role in reprogramming metabolism in certain tumor cells and has been shown to enhance aerobic glycolysis by directly activating genes, such as HK2, PKM1 and LDHA (Shim et al., 1997; Dang et al., 2009) . The transcription factor hypoxia-inducible factor 1 (HIF1) also regulates glycolysis by enhancing the expression of glucose transporters, HKs and phosphofructokinases (PFKs) (Denko, 2008) .
HAMLET is a complex of partially unfolded alactalbumin and oleic acid, which preferentially kills cancer cells and immature cells . The broad tumoricidal activity includes leukemia cells, carcinoma cells and glioma cells, whereas healthy, differentiated cells survive HAMLET challenge (Fischer et al., 2004) . HAMLET thus appears to target highly conserved survival mechanisms that are crucial for cancer cells. This selectivity has been confirmed in vivo in a human glioblastoma xenograft model and in a murine bladder cancer model (Fischer et al., 2004; Mossberg et al., 2010) . In clinical studies of skin papillomas and bladder cancers Mossberg et al., 2007) HAMLET showed tumoricidal activity with limited side effects.
This study investigated the molecular basis of HAM-LET sensitivity in cancer cells, using screening techniques to detect features of transcription, protein interaction and metabolism that alter survival after HAMLET exposure. We show that sensitivity to HAMLET is dependent on c-Myc and glycolysis and identified the glycolytic enzyme HK1 as a potential direct target of HAMLET. The results also indicated that HAMLET alters cancer cell metabolism and that it may disrupt glycolysis, which is altered in cancer cells due to the Warburg effect.
Results
An shRNA screen identifies c-Myc and glycolytic-related proteins as modifiers of HAMLET sensitivity To get an unbiased overview of genes important for HAMLET sensitivity, we used the RNA interference barcode screening technology (Brummelkamp and Bernards, 2003; Silva et al., 2005 Silva et al., , 2008 . Barcode screens use DNA microarrays to follow the relative abundance of each small-hairpin RNA (shRNA) vector in a large population of cells infected with a shRNA vector library (Figure 1a) . Using retroviral infection, we introduced a collection of 4603 shRNAs designed to target 1650 cancer-related human genes (Silva et al., 2005) for suppression by RNA interference into A549 lung carcinoma cells, which are known to be HAMLET sensitive. The infected cells were split into three pools, one of which was left untreated and used as a reference, whereas the other two were exposed to low (7 mM) and high (35 mM) concentrations of HAMLET. After 2 h of HAMLET treatment, we recovered shRNA cassettes by PCR amplification and analyzed their relative abundance by hybridization to DNA microarrays as described previously (Zender et al., 2008) .
A small number of shRNA vectors were enriched or depleted in the population treated with HAMLET; 43 inhibitory and 44 sensitizing shRNAs showed an absolute MaxMean score of 40.5 in both high-and low-dose treatment groups or an absolute score of 42 in any group (Figure 1b and Supplementary Table S1 ). The identified genes included oncogenes like c-Myc and glycolysis-related proteins. shRNAs against HK1 and HIF1a sensitized the cells to HAMLET (Figures 1c and  d) , suggesting that increased HK1 and HIF1a expression drives a phenotype more resistant to HAMLET. In contrast, shRNA targeting 6-phosphofructo-2-kinase/ fructose-2,6-biphosphatase (PFKFB1) and c-Myc rescued the cells (Figures 1c and d) . Biological pathways enriched for by HAMLET were identified by gene set enrichment analysis (GSEA) using the canonical pathways gene set collection. The GSEA algorithm tests for the enrichment of a set of items within a larger ranked list of such items. The identified pathways confirmed the importance of glycolysis, as four glycolysis-related pathways significantly modified HAMLET sensitivity (Figures 1e and f) . In addition, the Ras pathway, which governs c-Myc expression, was identified as a determinant of HAMLET sensitivity (Figure 1f ).
The shRNA screen suggested that oncogenic transformation by c-Myc sensitizes cells to HAMLETinduced cell death and that the glycolytic machinery influences HAMLET sensitivity of cancer cells.
The c-Myc oncogene determines the tumoricidal effect of HAMLET We subsequently examined whether HAMLET sensitivity reflects c-Myc expression levels. Human lung carcinoma cells (A549), kidney carcinoma cells (A498) and semi-differentiated healthy kidney cells (human renal proximal tubule cells) were exposed to HAMLET (21 mM), and ATP levels monitored (Figure 2a) . A rapid reduction in ATP levels was observed in lung and kidney carcinoma cells but healthy cells remained unaffected after 3, 6 and 24 h. However, at higher HAMLET concentrations, a partial response was also seen in those cells (Supplementary Figure S1A) . The difference in cMyc expression reflected the difference in HAMLET sensitivity, as lung and kidney carcinoma cells show higher expression of c-Myc than healthy cells (Figures  2b and c) .
To address whether c-Myc activity influences HAMLETinduced cell death, A549 lung carcinoma cells were transiently transfected with inhibitory c-Myc shRNAs or irrelevant shRNA and reduction in c-Myc expression was confirmed after 72 h (Figures 2d and e) . Cells with reduced c-Myc expression became more resistant to the lethal effects of HAMLET (21, 36 mM, 3 h), whereas cells transfected with irrelevant shRNA retained their sensitivity, with an LC 50 similar to untransfected cells (Figure 2f ). The results suggest that the level of c-Myc expression is a direct determinant of HAMLET susceptibility in cancer cells.
As knockdown of c-Myc causes growth arrest in many cell lines (Watson et al., 1991) , we deliberately induced growth arrest and tested the effect on HAMLET sensitivity. A549 lung carcinoma cells were subjected to serum withdrawal or doublethymidine block, and growth arrest was confirmed by flow cytometry after propidium iodide staining (Supplementary Figure S1b) . However, growth arrest did not significantly alter HAMLET sensitivity (Figure 2g ), indicating that the effect of c-Myc shRNA on HAMLET sensitivity is not dependent on a possible growth arrest induced by c-Myc knockdown.
Glucose deprivation and inhibitors of glycolysis enhance HAMLET-induced cell death
The shRNA screen and the GSEA analysis identified glycolysis-related proteins as determinants of HAMLET sensitivity. To directly address whether glycolysis modifies the sensitivity to HAMLET, A549 lung carcinoma cells were deprived of glucose for 30 min, HAMLET was added (21 and 36 mM) and cell death was quantified (15 min, 1 and 3 h). Glucose deprivation sensitized cells to HAMLET, causing a dramatic reduction in ATP levels and Trypan blue exclusion, as well as an increase in lactate dehydrogenase release and this effect was reversed by the addition of glucose (Figure 3a and Supplementary Figures S2) . In addition, glucose analog 2-deoxyglucose, which inhibits glycolysis, enhanced HAMLET toxicity in a dose-dependent manner (Figure 3b and Supplementary Figure S2) . 
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To further examine the effects of glucose on the cellular response to HAMLET, Alexa Fluor 568-labeled HAMLET was added to cancer cells stained with Hoechst and examined by real-time confocal imaging. Glucose-deprived cells showed more blebbing after 1 h than glucose-fed cells, and after 3 h, more of the glucosedeprived cells had changed morphology and showed strong HAMLET staining ( Figure 3c ). Furthermore, 3-bromopyruvate, which inhibits glycolysis and mitochondrial ATP production , significantly increased HAMLET-induced cell death (Supplementary Figure S2F ). Taken together, these results show that cancer cells are sensitized to the lethal effects of HAMLET when glycolysis is inhibited. In a far-western dot blot, HAMLET bound strongly to human HK1 but not to the other three proteins. Recombinant human His-tagged HK1 and PKM2, rabbit muscle GPI and BSA were spotted onto PVDF membranes and incubated with HAMLET (HL) or a-lactalbumin (ALA) (both 0.2 mg/ml) or buffer as control. Bound HAMLET or a-lactalbumin was detected using goat anti-a-lactalbumin and HRP-conjugated rabbit anti-goat antibodies and quantified using ImageJ software. Mean of four (HK1 and PKM2) or seven (GPI, BSA) experiments þ s.e.m. for HAMLET. Results from one experiment for a-lactalbumin. (c) HAMLET colocalized with HK1 especially in the perinuclear region. A549 cells were treated with Alexa Fluor 568-labeled HAMLET (HL, red) for 15 min and stained with anti-HK1 and Alexa Fluor 488-labeled antibodies (green). Scale bars: 20 mM. (d) HAMLET reduced HK activity but not pyruvate kinase or glucose-6-phosphate isomerase activity, in a dose-dependent manner. A549 cells were treated with different HAMLET concentrations for 15 min, lysed and activity in the lysates was quantified by a coupled spectrophotometric assay. Mean of three experiments þ s.e.m.
Metabolism and c-Myc defines HAMLET sensitivity P Storm et al with a Z-score of 5.09 ( Figure 4a ) was one of the top scoring hits. In addition, several glycolytic enzymes showed increasing signal intensity with rising HAMLET concentrations but with lower Z-scores, thus not meeting the stringent criteria for a positive hit in this screen (Z-score 43 and replicate spot and inter-array coefficient of variation (CV)o50%). These enzymes included PFKFB2 and PFKFB4 (Z-score 0.3 and 0.9, respectively), GAPDH (glyceraldehyde-3-phosphate dehydrogenase, Z-score 0.5) and PKM2 (Z-score 0.1). To confirm the binding of HAMLET to the glycolytic enzymes, polyvinylidene fluoride membranes were spotted with recombinant His-tagged human HK1 and PKM2, rabbit glucose-6-phosphate isomerase (GPI, 93% identical with human) and bovine serum albumin as a negative control. The membranes were sequentially incubated with HAMLET or a-lactalbumin, goat antia-lactalbumin antibody and rabbit anti-goat horseradish peroxide-conjugated antibody. HAMLET bound strongly to human HK1 but not to human PKM2, rabbit GPI or bovine serum albumin (Figure 4b ). This strong interaction was not seen with a-lactalbumin, suggesting that the HAMLET complex has significantly higher affinity for HK1 than the native, fatty acid-free protein.
Confocal microscopy was used to visualize the interaction of HAMLET with HK1 in cancer cells. A549 lung carcinoma cells were treated with Alexa Fluor 568-labeled HAMLET (15 min, 21 mM), fixed and stained with anti-HK1 antibodies (Figure 5c ). Metabolism and c-Myc defines HAMLET sensitivity P Storm et al Cells stained with anti-PKM2 antibodies were used as controls (Supplementary Figure S3) . Untreated cells showed granular HK1 staining with the highest intensity in the perinuclear region (Figure 5c ). In HAMLETtreated cells, a strong colocalization between HAMLET and HK1 was observed especially in perinuclear, rounded aggregates. In contrast, only a weak colocalization of PKM2 with HAMLET was detected (Supplementary Figure S3 ).
HAMLET reduces HK activity in cancer cells
To determine whether HAMLET disturbs glycolysis in cancer cells, HK, PK and GPI activities were measured in detergent-free lysates from HAMLET-treated A549 lung carcinoma cells (7, 21 and 36 mM) by coupled spectrophotometric assays. HK activity showed a dosedependent trend towards a decrease after 15 min of HAMLET treatment (Figure 4d ), but GPI and PK activities were not significantly altered. At this early time point, there were no changes in cell morphology or in cellular HK1 levels (Supplementary Figures S4a and b) . ATP levels decreased in a dose-dependent manner already at 15 min but lactate production was only reduced after 3 h (Supplementary Figure S4c) . The results suggest that HAMLET may reduce HK activity in lung carcinoma cells.
Knockdown of HK1 or PFKFB1 modulates HAMLET sensitivity
To verify the shRNA screen and to further examine the role of glycolysis-related proteins in HAMLET-induced cell death, A549 lung carcinoma cells were transiently transfected with small-interfering RNAs (siRNAs) targeting HK1, PFKFB1 and PKM2. Knockdown was confirmed by qPCR and western blots (Figures 5a, b and e), and sensitivity to HAMLET was quantified by measuring ATP levels and Trypan blue exclusion (Figures 5c and d) . HK1 siRNA-transfected cells showed a more pronounced loss of ATP in response to HAMLET (21 and 36 mM, Po0.05) than untransfected cells or cells transfected with control siRNA. In contrast, PKM2 siRNA did not change the sensitivity to HAMLET (Figure 5c ). Similar results were observed with Trypan blue exclusion. Furthermore, knockdown of PFKFB1, which conferred resistance in the shRNA screen, decreased the sensitivity to HAMLET (Figure 5d ). These results confirm that knockdown of HK1 and PFKFB1 increases and reduces HAMLET sensitivity, respectively.
HAMLET rapidly disrupts cancer cell metabolism To assess whether HAMLET changes the metabolic state of cells, we compared the metabolomic profile of HAMLET-treated lung carcinoma cells (36 mM, 15 min and 1 h) with that of untreated cells ( Figure 6 and Supplementary Figure S5) . Three different untargeted metabolite profiling methods were used to study the possible metabolic effects of HAMLET. Reverse-phase liquid chromatography coupled to electrospray ionization mass spectrometry (LC-MS) was used to compare hydrophobic metabolites (such as lipids), hydrophilic interaction chromatography, and LC-MS was used to study a wide range of polar metabolites, and gas chromatography mass spectrometry (GC-MS) to profile core metabolites (Baran et al., 2009) . By reverse-phase LC-MS profiling, 560 features were detected (including different adducts, isotopes and in-source degradation products of the same metabolite) defined by m/z value and LC retention time (for the combination of m/z value and retention time, see Figure 6a ). The analysis revealed that 125 of the 560 features were significantly altered after 15 min of HAMLET treatment (107 increased, 18 reduced). After 1 h, the majority of 76 altered features were instead reduced (22 increased, 54 reduced) ( Figure 6d ). As expected from the uptake of HAMLET, features with the largest signal intensity in HAMLETtreated cells at both time points and several features with similar retention time were putatively identified as different ionization and isotope variants of oleic acid, the lipid component of HAMLET, based on exact mass and LC retention time. Untargeted profiling using hydrophilic interaction chromatography LC-MS was consistent with the reverse-phase analysis, showing significant metabolic alterations after HAMLET treatment. Of the 1120 features that were detected, 103 were found to change after 15 min (28 were increased, 75 were reduced in HAMLET-treated cells) and 114 after 1 h of HAMLET treatment (64 were increased, 50 were reduced in HAMLET-treated cells). Several of these metabolites were identified based on comparison of exact mass a nd retention time with analytical standards. S-adenosyl-L-homocysteine, creatine, phosphocreatine, taurine and glutathione disulfide all decreased in HAMLETtreated cells, possibly reflecting a disruption in amino acid metabolism and oxidative stress. The identity of creatine and glutathione disulfide was also confirmed by subsequent MS/MS analysis. The results indicate that HAMLET rapidly alters cancer cell metabolism.
The GC-MS profiling of cellular metabolites was subsequently performed in A549 lung carcinoma cells treated with HAMLET for 15 and 60 min. By hierarchical clustering, three separate clusters were observed, the first containing control samples (15 and 60 min), the second HAMLET-treated samples obtained after 15 min and the third 60 min samples, respectively (Figure 7a , Supplementary Table S2 ). Overall metabolite concentrations were lower in HAMLET-60 samples than in controls, confirming the general shut down of metabolism identified in the untargeted profiling. To derive significantly altered metabolites, a linear model was fitted to the data and metabolites with an absolute log 2-fold change of 1 and false discovery rate (FDR)-adjusted P-values o0.05 were considered significant. In all, 20 metabolites were significantly altered after 15 min of HAMLET treatment ( Figure 7b ). As expected from the known uptake of HAMLET, oleic acid and its derivative elaidic acid showed the most marked increase (120-fold, adjusted P-value ¼ 4 Â 10
À6
and 84 and 8.1 Â 10 À6 , respectively). In addition, a number of other
Metabolism and c-Myc defines HAMLET sensitivity P Storm et al metabolites were more abundant after 15 min, including gluconic acid (3.3-fold), gluconate-lactone (2.6-fold), glyceric acid (2-fold) and pyruvate (1.7-fold). Among the metabolites that were significantly reduced were taurine, glycine, the citric acid cycle intermediate aconitate and the polyamines putrescine and spermidine. After 1 h, 41 metabolites were identified as significantly altered (Figure 7b ). Oleic acid (log2-fold change of 5.1 and P ¼ 2 Â 10 À10 ) showed the second most marked increase together with its derivatives, including elaidic acid and palmitoleic acid. Pyruvate and several intermediates in the citric acid cycle, including succinate, aconitate, fumarate and malate, were less abundant after HAMLET treatment, confirming the inhibitory effect of HAMLET on glycolysis. In addition, a number of other key metabolites metabolism were reduced, including aspartate, glutamate and spermidine. Finally, confirming the untargeted metabolomic analysis, HAMLET caused a depletion of metabolites relating to glutathione metabolism. Taken together, these results show that HAMLET rapidly causes a massive alteration of cancer cell metabolism which may in part result from a disruption of glycolysis. , 2000) . In addition to its ability to kill cancer cells in vitro, HAMLET has shown therapeutic efficacy against skin papillomas and rapid topical effects on human bladder cancers Mossberg et al., 2007) . In animal models of human glioblastoma or bladder cancer, HAMLET has been shown to prolong survival and delay tumor development (Fischer et al., 2004; Mossberg et al., 2010) . So far, toxic effects on healthy tissues have not been detected, suggesting that HAMLET exploits conserved features of cancer cells for its activity. Some of these conserved features were identified here. HAMLET sensitivity of cancer cells was shown to be dependent on the c-Myc oncogene expression and the glycolytic machinery, especially HK1 and PFKFB1, and HIF1a, which is activated by hypoxia and oncogene activity and acts by enhancing the transcription of glycolytic enzymes, glucose transporters and lactate dehydrogenase (Kim et al., 2006; Papandreou et al., 2006) . c-Myc has been called 'the quintessential oncogene' (Li et al., 1984; Nilsson and Cleveland, 2003) but the effects remain paradoxical, as introduction of c-Myc alone in normal cells causes cell death (Evan et al., 1992) . In cancer cells, c-Myc overexpression influences at least 30% if not all expressed genes, either directly or through different regulatory circuits. As HAMLET has shown activity against 440 different tumor cell types from different species, tissues and individuals, the sensitizing effect of the ubiquitous oncogene c-Myc was not entirely unexpected. Tumor cells which expressed higher levels of c-Myc died more easily when exposed to HAMLET than did healthy differentiated cells, and knockdown of c-Myc decreased HAMLET sensitivity. The c-Myc oncogene has been proposed to promote the Warburg effect and the dependence of cancer cells on aerobic glycolysis. Thus, overactive c-Myc may make cancer cells overly sensitive to a deregulation of glycolysis by HAMLET. In addition to c-Myc itself, the Ras signaling pathway was identified as a determinant of HAMLET sensitivity by GSEA analysis and c-Myc is activated downstream of Ras, thus controlling cell proliferation and survival together with other effectors such as phosphoinositide 3-kinase. We have found that HAMLET causes a shift from mitogen-activated protein kinase kinase/extracellular signal-regulated kinase to p38 signaling in tumor cells and that p38 is involved in the early cell death response to HAMLET (Storm et al., manuscript in preparation). Healthy cells, in contrast, are characterized by low intrinsic activity in the Ras/mitogen-activated protein kinase pathway and c-Myc expression and maintain a balanced mitogen-activated protein kinase activity during HAMLET exposure, with little p38 activation, consistent with their low HAMLET sensitivity. Oncogene addiction and high metabolic activity caused by mutant c-Myc in cancer cells may make these cells overly sensitive to deregulation of glycolysis by HAMLET, further linking the effects of c-Myc to cancer cell death.
Besides c-Myc, HIF1a, a second oncogene well-known to modulate cancer cell metabolism, was implicated in regulating sensitivity to HAMLET. HIF1a acts by enhancing the transcription of critical constituents of the glycolytic machinery, including glucose transporters and HK1 (Dang et al., 2008) . It has been proposed that HIF1 alone can drive the major metabolic changes that accompany oncogenic transformation, as identified by Otto Warburg (Denko, 2008) . This synergy is consistent with the HAMLET-sensitizing effects of HK1 and HIF1 in the shRNA screen. In addition, deregulated expression of oncogenic c-Myc collaborates with HIF1a to confer the tumor metabolic phenotype. Paradoxically, under physiological conditions, HIF1a can inhibit the activity of c-Myc and HIF1a directly influences the expression of MXI1, which binds MAX, thereby antagonizing the effects of cMyc (Zhang et al., 2007) . HIF1a also decreases c-Myc activity by attenuating c-Myc protein levels through a proteasome-dependent pathway. In contrast to HIF1a, HIF2a has been shown to stabilize the MYC-MAX complex, thereby stimulating c-Myc-induced transcription. Therefore, the effects of c-Myc on HAMLET sensitivity are not likely to only reflect its regulation of glycolysis. In this regard, context-dependent c-Myc-mediated transcription is crucially important for tumor progression and may be so for HAMLET sensitivity as well.
The glycolytic state of tumor cells was defined as a determinant of HAMLET sensitivity by the shRNA screen, and extracellular glucose levels were shown to modulate the sensitivity of tumor cells to HAMLET. Furthermore, the GSEA analysis of the shRNA screen identified several pathways related to glycolysis as important for HAMLET sensitivity. HK1 was a direct target for HAMLET, as seen by binding in a proteomic screen involving 8000 proteins and in dot blots in which the purified human HK1-HAMLET interaction was confirmed. Inhibition of HK1 and the HK1 homolog HK2 would be predicted to reduce glucose phosphorylation, thereby creating a state similar to glucose deprivation by inhibiting glycolysis in cancer cells. The HK1/2 isoforms are associated with the mitochondrial membrane, where they control glucose utilization. In addition, HK1 decreases voltage-dependent anion channel conductance, thus protecting cells from cytochrome c release and apoptotic death (Abu-Hamad et al., 2008) . In a parallel study, we have shown that ion channel activation is a critical membrane event in HAMLET-induced cell death (Storm et al., manuscript in preparation), raising the possibility that in addition to its effects on glycolysis, HK1 acts by modulating the interaction of HAMLET with ion channels in the mitochondrial membrane. We have also seen that peroral HAMLET treatment of APC min mice with colon cancer modified the transcription of a number of glycolysis-related proteins (Puthia et al., manuscript in preparation), suggesting relevance of these targets also in vivo.
The shRNA screen also identified PKFKB1 as a significant determinant of HAMLET sensitivity, but in contrast to HK1, PKFKB1 shRNA had protective effects. The mechanism behind this is not immediately obvious as the four PFKFB isoforms possess opposing kinase and bisphosphatase activities, with independent domains catalyzing the synthesis or degradation of fructose-2,6-biphosphate, respectively. The resulting effect on glycolysis is determined by the overall kinase:bisphosphatase ratio in each cell. PFKFB1, PFKFB2 and PFKFB4 have near equal kinase and bisphosphatase activities, whereas PFKFB3 has stronger kinase activity (740:1) and is overexpressed in cancer cells (Yalcin et al., 2009 ). Knockdown of PFKFB1 may increase the dominance of the PFKFB3 isoform resulting in higher fructose-2,6-bisphosphate levels and enhanced glycolysis. This would be consistent with rescue after PFKFB1 knockdown, as reduced glycolysis in a cell with the Warburg phenotype seems to favor HAMLET-induced cell death.
Finally, a broad metabolomic screen demonstrated that HAMLET-treated cells rapidly loose metabolic activity. HAMLET triggered rapid and profound changes in the metabolic state of cancer cells, as shown by LC-MS and GC-MS profiling. After 1 h, the majority of metabolites showed a reduction in intensity, consistent with the rapid suppression of glycolysis and a resulting loss of energy required to maintain the normal metabolic machinery, especially in cancer cells. The shift was dramatic, and it is plausible that the rapid cell death response to HAMLET may result, in part, from this effect, as cells deprived of energy and metabolic activity, are known to undergo cell death (Kroemer and Pouyssegur, 2008) . MS/MS analysis identified metabolites that were strongly reduced, including S-adenosyl-Lhomocysteine, creatine, phosphocreatine, taurine and glutathione disulfide, which are fundamental intermediates in the defense against oxidative stress (Balendiran et al., 2004) . Targeted GC-MS profiling identified large amounts of oleic acid in HAMLET-treated tumor cells already after 15 min, indicating that excess amounts of fatty acid and saturation of the fatty acid metabolism machinery might be responsible for the first, rapid response to HAMLET. We could consistently see a depletion of important glutathione intermediates at later time points. The increased activity in the anti-oxidant pathways together with p38 activation might indicate that reactive oxygen species are important for HAM-LET-induced cell death.
Interest in the metabolic changes in cancer cells, such as their higher rates of glycolysis has been reawakened by the discovery that mutations in well-known oncogenes affect cancer cell metabolism and the advent of new technologies for studying a cell's metabolome. Clearly, metabolic pathways are highly interconnected with pathways that govern the classical hallmarks of cancer, such as uncontrolled proliferation and resistance to cell death. Thus, inhibition of glycolysis is becoming an important new therapeutic target. The glucose analog 2-deoxyglucose has been shown to kill several cancer cell lines in vitro, to inhibit the growth of pancreatic cancer cells in nude mice and to enhance the effects of death receptor ligands, radiation and cytotoxic drugs (Coleman et al., 2008; Hernlund et al., 2008) . At present, 2-deoxyglucose is in clinical trials as single agent or in combination therapy. In addition, 3-bromopyruvate eradicated advanced cancers in rats without apparent adverse effects (Ko et al., 2004) . HAMLET presents a new therapeutic option, potentially acting more broadly by inhibiting glycolysis and other cellular pathways regulated by c-Myc-and Rasdependent transformation. The lack of HAMLET sensitivity in healthy, differentiated cells and the lack of in vivo toxicity in different tumor models also add to HAMLET's clinical potential.
Materials and methods
HAMLET production and cell culturing a-Lactalbumin was purified from human milk and converted to HAMLET by removal of calcium and binding to oleic acid as previously described (Svensson et al., 2000) . For microscopy, HAMLET was labeled with Alexa Fluor 568 (Invitrogen, Carlsbad, CA, USA). The A498 human kidney carcinoma cell line, the A549 human lung carcinoma cell line and the Jurkat human acute T-cell leukemia cell line (obtained from ATCC, Manassas, VA, USA) were cultured as described previously (Brest et al., 2007) . Human renal proximal tubule cells derived from healthy adult kidney (Lonza, Basel, Switzerland) were grown in Dulbecco's modified Eagle's medium/F12 medium with 15% fetal calf serum.
Cell death assays, microscopy and cell cycle analysis HAMLET was added to cells in the serum-free medium, and for longer incubations, fetal calf serum was added after 1 h. Where required, cells were pre-incubated in glucose-free RPMI (Sigma-Aldrich (St Louis, MO, USA) or Invitrogen), 2-deoxyglucose or 3-bromopyruvate (both Sigma-Aldrich). After HAMLET treatment, cytotoxicity was determined by quantifying lactate dehydrogenase release (CytoTox kit, Promega, Madison, WI, USA), ATP levels (ATPlite kit, Perkin-Elmer (Boston, MA, USA) or CellTiter-Glo kit, Promega), remaining cell numbers or Trypan blue exclusion. For live cell microscopy, cells were seeded in a 35-mm glass-bottom dish, nuclei were stained with Hoechst 33342 (Invitrogen), Alexa Fluor 568-labeled HAMLET (21 mM) was added and cells were examined on an inverted LSM 510 DUO confocal microscope (Carl Zeiss, Jena, Germany). For colocalization experiments, cells were seeded on 8-well chamber slides, fixed in 4% formaldehyde, permeabilized with 0.1% Triton X-100, stained with anti-HK1 (Cell Signaling Technology, Danvers, MA, USA) or anti-PKM2 (Millipore, Billerica, MA, USA) antibodies, followed by secondary antibodies labeled with Alexa Fluor 488. Cells were examined on an inverted LSM 510 META confocal microscope (Carl Zeiss). For cell growth inhibition, A549 cells were cultured in 0.5% fetal calf serum for 48 h or treated with thymidine (Sigma-Aldrich, 2 mM in RPMI 1640 with 5% fetal calf serum) for 16 h, followed by 16 h in normal media and another 16 h in thymidine-containing media (Thomas and Lingwood, 1975) . Cell cycle analysis was performed on a FACSCalibur device (BD Biosciences, San Jose, CA, USA) after fixation in 80% methanol and staining with propidium iodide (Sigma-Aldrich).
shRNA screen The microRNA-based shRNA library used for screening was pooled from several focused sets composed of 10 000 shRNAs targeting B3000 cancer-relevant genes. Retrovirus was prepared from packaging cells, and the viral supernatant was used to infect A549 cells at single copy integration per cell. After puromycin selection, three groups of cells each in triple replicates were used for HAMLET treatment: mock treatment with vehicle, low dose (IC 20 , 7 mM) and high dose (IC 80 , 35 mM). After 2 h of incubation at 37 1C, genomic DNA was extracted from cell pellets, and a 350-bp fragment harboring full barcode and half hairpin was amplified by PCR, purified, labeled with fluorescence dye and hybridized to the Agilent 8-plex array chips (Agilent, Santa Clara, CA, USA). All slides were processed following the manufacturer's instructions and scanned using an Axon 4000B scanner (Axon Instruments, Sunnyvale, CA, USA) at 5 mm per pixel resolution. After normalization (Smyth and Speed, 2003) , signals from duplicate features were averaged, values were log 2-transformed and changes were scored using the MaxMean method. For GSEA analysis, the javaGSEA Desktop Application was used (http:// www.broadinstitute.org/gsea/) with the c2.cp.v.25 gene set collection comparing all HAMLET-treated samples (n ¼ 8) against phosphate-buffered saline-treated controls (n ¼ 4). P-values were derived by 10 000 permutation of the gene sets.
RNA interference and qPCR c-Myc shRNA experiments were performed using Fugene HD (Roche Diagnostics, Mannheim, Germany) at a ratio of 4:2 with plasmids generating shRNAs to c-Myc (Genecopoeia, Rockville, MD, USA). HK1, PFKFB1 and PKM2 siRNA (Qiagen, Hilden, Germany) were transfected using Lipofectamine 2000 (Invitrogen). After 42 h (HK1, PKM2, PFKFB1) or 72 h (c-Myc), knockdown was examined by qPCR and western blot and cells were used for viability assays. For qPCR, RNA was prepared using the RNeasy kit (Qiagen) and real-time PCR was performed on a Rotorgene 2000 (Corbett Life Science, Sydney, Australia) or ABI 7500 instrument (Applied Biosystems, Foster City, CA, USA) using QuantiTect Primer Assays for HK1, PFKFB1, PKM2 and PPIA (Qiagen).
Western blot
Cells were washed with ice-cold phosphate-buffered saline and lysed in NP-40 buffer, modified RIPA buffer or SDS buffer containing complete protease inhibitor cocktail (Roche Diagnostics). Equal amounts of protein or, for siRNA experiments, equal volumes of lysates derived from the same number of cells were separated by SDS-PAGE and blotted onto polyvinylidene fluoride membranes. Membranes were incubated with rabbit anti-c-Myc (Epitomics, Burlingame, CA, USA), mouse anti-actin (Sigma-Aldrich), rabbit anti-PKM2 (Cell Signaling Technology), rabbit anti-HK1 (Millipore), rabbit anti-PFKFB1 (Abcam, Cambridge, UK) or mouse anti-GAPDH antibody (Novus Biologicals, Littleton, CO, USA) overnight at 4 1C and bound antibodies were detected using corresponding horseradish peroxide-conjugated secondary antibodies.
Protein array and HAMLET overlay A screen for possible interaction partners for HAMLET was performed on a ProtoArray Human Protein Microarray v4.0 using Invitrogen's Protein-Protein Interaction Profiling Service at Invitrogen as described previously (Satoh et al., 2006) . In brief, arrays were probed with Alexa Fluor 568-labeled HAMLET in 2 concentrations (5 and 50 ng/ml) in duplicate, and signals were compared with a negative control array incubated without HAMLET. Proteins were defined as positive hits if the Z-score was >3 s.d. above the mean protein signal on at least one array probed with HAMLET and o1 s.d. above for the control array, the Z-factor was >0.5 for the corresponding array (indicating a signal 2-fold above the noise), the replicate spot CV was o50% on the corresponding array and the inter-assay CV for the protein was o0% on the corresponding arrays. For the HAMLET far-western dot blot, 0.5 mg human recombinant His-tagged HK1 and PKM2 (Abcam), rabbit muscle GPI and bovine serum albumin (Sigma-Aldrich) were spotted onto polyvinylidene fluoride membranes and blocked with Sat-1 and Sat-2 . Next, membranes were incubated overnight at 4 1C with goat anti-a-lactalbumin antibodies (Bethyl Laboratories, Montgomery, TX, USA) and 2 h at room temperature with horseradish peroxide-conjugated rabbit anti-goat antibodies (Sigma-Aldrich). To quantify protein binding, dot intensity was measured using ImageJ software (http://rsbweb.nih.gov/ij/).
Glycolytic enzyme and lactate assays
To measure glycolytic enzyme activities, cells were treated with HAMLET, scraped into Tris-HCl buffer (pH 7.5) and homogenized by sonication. PK activity was measured as NADH consumption in a continuous spectrophotometric assay coupled to lactate dehydrogenase. HK and GPI activities were measured as NADPH formation in continuous spectrophotometric assays coupled to glucose-6-phosphate dehydrogenase. Consumption of NADH and formation of NADPH were measured by the change in absorbance at 340 nm. All enzymes and reagents were obtained from Sigma-Aldrich. For the lactate assay, cells were treated with HAMLET in medium without added sodium pyruvate, the medium was collected and lactate levels measured using the Lactate Assay kit (Biovision, Mountain View, CA, USA).
Metabolomics
HAMLET-treated cells were pelleted, snap frozen in dry icechilled acetone and stored at À80 1C. Chemicals were purchased from Sigma-Aldrich or Honeywell (Morristown, NJ, USA) and were of the highest purity. For metabolite extraction, samples were resuspended in phosphate-buffered saline, lysed and extracted with methanol and a second time with isopropanol. LC-MS reverse-phase chromatography were performed on a Zorbax C18 column (Agilent) with 5 mm particles at a flow rate of 20 ml/min. Chromatography was performed as follows (buffer A: H 2 O with 0.1% formic acid; buffer B: acetonitrile with 0.1% formic acid): equilibration in 3% buffer B for 3 min, 3-50% buffer B gradient over 5 min, 50-99% buffer B gradient over 25 min, 99% buffer B for 10 min, wash with a solution of acetone and isopropanol (1:1) for 10 min and re-equilibration in 3% buffer B for 10 min. LC-MS normal-phase chromatography were performed on a Acquity UPLC HILIC column (Waters Corporation, Milford, MA, USA) with 1.7 mm particles at a flow rate of 20 ml/min. Chromatography was performed as follows (buffer A: H 2 O with 5 mM ammonium acetate; buffer B: 90% acetonitrile with 5 mM ammonium acetate): equilibration in 100% buffer B for 4 minutes, 100-45% buffer B gradient over 26 minutes and isocratic elution with 45% buffer B for 10 minutes (all mixtures with buffer A). Data were collected using an Agilent ESI-QTOF and a capillary voltage of 4000 V. Custom software written in the Matlab programming language (MathWorks, Natick, MA, USA) was used to define features within each sample and compare them across samples. Signal intensities of quadruplicate samples were averaged and features with an absolute log 2-fold change X1 and Pp0.05 (Wilcoxon's ranksum test) were considered to be significantly altered.
For GC-MS analysis, HAMLET-treated cells were washed with phosphate-buffered saline, followed by the addition of icecold methanol to stop metabolic activity. Subsequently, cells were scraped into the solvent and transferred to a reaction tube. Six replicates consisting of three pooled wells each were collected per sample group. For extraction, the methanol phase was removed from the cells, dried and stored at À80 1C. Cell pellets were dried in a FreeZone 2.5 lyophilizer (Labconco, Kansas City, MO, USA), homogenized using a Mini-Beadbeater (BioSpec Products, Bartlesville, OK, USA) and extracted a pre-cooled methanol-isopropanol-water (3:3:2) mixture. The
